{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T03:36:14Z","timestamp":1781062574743,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jgo.2020.03.005","type":"journal-article","created":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T09:13:07Z","timestamp":1583831587000},"page":"1274-1278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["The characteristics, treatment patterns, and outcomes of older adults aged 80 and over with multiple myeloma"],"prefix":"10.1016","volume":"11","author":[{"given":"Mark A.","family":"Fiala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C.","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya M.","family":"Wildes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgo.2020.03.005_bb0005","series-title":"Enrollment of Older Adults in Clinical Trials Evaluating Patients with Hematologic Malignancies \u2013 the Food and Drug Administration (FDA)","author":"Kanapuru","year":"2017"},{"key":"10.1016\/j.jgo.2020.03.005_bb0010","unstructured":"Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. (eds). SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, https:\/\/seer.cancer.gov\/csr\/1975_2016\/, based on November 2018 SEER data submission, posted to the SEER web site, April 2019."},{"issue":"3","key":"10.1016\/j.jgo.2020.03.005_bb0015","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.jgo.2020.03.005_bb0020","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and Prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.jgo.2020.03.005_bb0025","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.jgo.2020.03.005_bb0030","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv."},{"issue":"15","key":"10.1016\/j.jgo.2020.03.005_bb0035","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2006.09.0100","article-title":"Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003","volume":"25","author":"Kristinsson","year":"2007","journal-title":"JCO."},{"issue":"5","key":"10.1016\/j.jgo.2020.03.005_bb0040","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in long-term survival of younger patients with multiple myeloma","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.jgo.2020.03.005_bb0045","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/leu.2014.23","article-title":"Improved long-term survival in multiple myeloma up to the age of 80 years","volume":"28","author":"Kristinsson","year":"2014","journal-title":"Leukemia."},{"issue":"5","key":"10.1016\/j.jgo.2020.03.005_bb0050","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia."},{"key":"10.1016\/j.jgo.2020.03.005_bb0055","doi-asserted-by":"crossref","unstructured":"Nandakumar B, Binder M, Dispenzieri A, Kapoor P, Buadi F, Gertz MA, et al. Continued improvement in survival in multiple myeloma (MM) including high-risk patients [Abstarct 8039]. ASCO Annual Meeting 2019. Chicago, IL.","DOI":"10.1200\/JCO.2019.37.15_suppl.8039"},{"issue":"3","key":"10.1016\/j.jgo.2020.03.005_bb0060","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clml.2018.01.005","article-title":"Undertreatment of older patients with newly diagnosed multiple myeloma in the era of novel therapies","volume":"18","author":"Fakhri","year":"2018","journal-title":"Clin. Lymph. Myeloma Leuk."},{"issue":"9","key":"10.1016\/j.jgo.2020.03.005_bb0065","doi-asserted-by":"crossref","first-page":"e363","DOI":"10.1016\/j.clml.2018.06.008","article-title":"Multiple myeloma patients ineligible for randomized controlled trials have poorer outcomes irrespective of treatment","volume":"18","author":"Malecek","year":"2018","journal-title":"Clin. Lymph. Myeloma Leuk."},{"key":"10.1016\/j.jgo.2020.03.005_bb0070","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov). Documentation for SEER Data. SEER. https:\/\/seer.cancer.gov\/data-software\/documentation\/. Accessed January 2, 2020."},{"issue":"8 Suppl","key":"10.1016\/j.jgo.2020.03.005_bb0080","article-title":"Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population","volume":"40","author":"Warren","year":"2002","journal-title":"Med. Care"},{"key":"10.1016\/j.jgo.2020.03.005_bb0085","unstructured":"National Cancer Institute. How the SEER & Medicare Data are Linked. https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/overview\/linked.html. Accessed April 29, 2019."},{"issue":"1","key":"10.1016\/j.jgo.2020.03.005_bb0090","doi-asserted-by":"crossref","DOI":"10.1200\/CCI.17.00089","article-title":"Development of an algorithm to distinguish smoldering versus symptomatic multiple myeloma in claims-based data sets","author":"Fiala","year":"2017","journal-title":"JCO Clin. Cancer Inform."},{"issue":"12","key":"10.1016\/j.jgo.2020.03.005_bb0095","first-page":"1258","article-title":"Development of a comorbidity index using physician claims data","volume":"53","author":"Klabunde","year":"2000","journal-title":"JCE"},{"issue":"18","key":"10.1016\/j.jgo.2020.03.005_bb0100","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2011-04-348367","article-title":"Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma","volume":"118","author":"Griffiths","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2020.03.005_bb0105","doi-asserted-by":"crossref","unstructured":"Zweegman S. Octogenarians with multiple myeloma. ASCO Annual Meeting 2019. Chicago, IL.","DOI":"10.1097\/HS9.0000000000000260"},{"issue":"34","key":"10.1016\/j.jgo.2020.03.005_bb0110","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"JCO."},{"issue":"5","key":"10.1016\/j.jgo.2020.03.005_bb0115","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.jgo.2020.03.005_bb0120","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/2040620711432020","article-title":"Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma","volume":"3","author":"Mateos","year":"2012","journal-title":"Therapeut. Adv. Hematol."},{"issue":"5","key":"10.1016\/j.jgo.2020.03.005_bb0125","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22888","article-title":"Clinical features and treatment outcome of elderly multiple myeloma patients with impaired renal function","volume":"33","author":"Chen","year":"2019","journal-title":"J. Clin. Lab. Anal."},{"issue":"7","key":"10.1016\/j.jgo.2020.03.005_bb0130","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/cam4.1128","article-title":"The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study","volume":"6","author":"Gregersen","year":"2017","journal-title":"Cancer Med."},{"key":"10.1016\/j.jgo.2020.03.005_bb0135","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/jnci\/dji189","article-title":"Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants","volume":"97","author":"Lamont","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"issue":"8","key":"10.1016\/j.jgo.2020.03.005_bb0140","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1182\/blood-2007-03-081018","article-title":"Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group","volume":"111","author":"Ludwig","year":"2008","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.jgo.2020.03.005_bb0145","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1600-0609.2012.01784.x","article-title":"Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era","volume":"89","author":"Dimopoulos","year":"2012","journal-title":"Eur. J. Haematol."}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406819303935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406819303935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:52:02Z","timestamp":1761817922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406819303935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1879406819303935"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2020.03.005","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The characteristics, treatment patterns, and outcomes of older adults aged 80 and over with multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2020.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}